Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476137 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 335
- Enrollment target
NCT01476137 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 335 participants.
The verdict
NCT01476137, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and endometrial cancer, and for patients with multiple myeloma.
Interventions
- DRUG GSK1120212
- DRUG GSK2110183
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2011-10-26 |
| Est. Completion | 2013-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476137
The ClinicalTrials.gov registry entry for NCT01476137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK1120212 is the first listed.
NCT01476137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476137 about?
NCT01476137 is a clinical study titled "A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers". The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and endometrial cancer, and for patients with multiple myeloma.
What is the current status of trial NCT01476137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 335 participants. The study started on 2011-10-26. Estimated completion is 2013-03-12.
What interventions are being tested in trial NCT01476137?
The interventions under investigation include: GSK1120212 (DRUG), GSK2110183 (DRUG).
Who is sponsoring clinical trial NCT01476137?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.